Results

1–9 of 9 results for Pegcetacoplan

Pegcetacoplan vs Avacincaptad Pegol in Geographic Atrophy: Anchored Matching-Adjusted Indirect Comparisons of Three Phase 3 Trials Over 24 Months
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2024
Clinical Utility of the Fellow Eye in Patients With Bilateral GA Due to AMD: Long-Term Data from the Pegcetacoplan Clinical Program
Diana V Do, MD, FASRS
Updates from the Field
2025
Pegcetacoplan Safety: Panel Recap
Andre J. Witkin, MD
Updates from the Field
2024
Safety of Intravitreal Pegcetacoplan for Geographic Atrophy: 12-Month Results of the OAKS and DERBY Trials
Caroline Baumal, MD
Annual Meeting Talks
2022
Debate: How Should We Treat Geographic Atrophy
Ajay E Kuriyan, MD, MS
Updates from the Field
2024
Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 DERBY and OAKS Trials
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2022
Impact of Baseline Imbalances on the Efficacy of Pegcetacoplan for the Treatment of GA: A Post Hoc Analysis of OAKS, DERBY, and FILLY
Sunir J. Garg, MD, FACS, FASRS
Updates from the Field
2022
Safety of Intravitreal Pegcetacoplan in Geographic Atrophy: Results from the Phase 3 DERBY and OAKS Trials
David S. Boyer, MD
Updates from the Field
2021
Efficacy of Intravitreal Pegcetacoplan in Geographic Atrophy: Results from the Phase 3 DERBY and OAKS Trials
Nathan C. Steinle, MD
Updates from the Field
2021